Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

New Tampa General Hospital center uses human and artificial intelligence to improve patient care

Published

5 years ago

on

Reading Time: 4 minutes

Today Tampa General Hospital launched a high-tech “mission control” clinical command center which uses artificial intelligence and predictive analytics to improve and better coordinate patient care at a lower cost.

The hospital’s new center is called CareComm and has been developed in partnership with GE Healthcare. It features 20 artificial intelligence apps, video walls with 38 large screens, 32 work stations, multiple computer systems, and a multi-disciplinary clinical team that includes doctors, nurses, and allied health professionals.

CareComm staff use these resources to predict the needs of patients and team members before they arise. With CareComm, Tampa General can anticipate potential roadblocks and issues in the care process, ensuring that rooms, equipment and medical professionals will be available for patients as soon as they’re needed.

Florida Gov. Ron DeSantis came to TGH for the CareComm unveiling on Tuesday and said he was impressed by the innovation.

“If you had told me we were in Kennedy Space Center in there, I probably would have believed you,” the governor said.  He said TGH staff had explained how CareComm helps different hospital departments collaborate and avoid communications silos. “They’ve broken down all these barriers and are able to achieve efficiencies and I think that’s great.”

“CareComm is a new center at Tampa General Hospital that harnesses technology and ingenuity to further improve healthcare,” DeSantis said. “Ensuring Floridians have access to higher quality and more affordable healthcare has been a priority of my administration. I look forward to seeing CareComm’s impact in the Tampa Bay Community.”

The center will improve quality while decreasing costs, said John Couris, president and CEO of Tampa General Hospital.

“CareComm is a huge step in our journey to become the safest and most innovative academic health system in the country,” Couris said. “We’re grateful to our physicians, nurses, staff, and our GE Healthcare partners for helping us leverage technology to drive quality up and costs down. This means better care and lower costs for patients.”

Several other elected officials attended the unveiling on Tuesday.

CareComm’s temporary facility, open since December, already has helped TGH reduce the average patient’s length of stay in the hospital by about half a day. This creates a better experience for patients who are ready to leave the hospital and also allows new patients to get to their rooms sooner. Reducing such inefficiencies has saved about $10 million – savings that ultimately benefit staff and patients.

All this data and analysis is focused on one goal – providing world-class care to patients in a more efficient way.

“CareComm helps us ensure that each patient gets the best possible care right when they need it,” said Dr. Pete Chang, vice president of Care Transitions. “Because our CareComm team is focusing on smoothing each patient’s journey through the hospital, our clinical team at the bedside has more time to spend with the patient.”

TGH doctors, nurses and administrators already work to manage the flow of patients, but it’s a complex task at a 1,007 bed academic medical center that on any given day treats people for cancer, traumatic accidents, heart attacks, infectious diseases and transplant operations.

CareComm uses the best of human ingenuity and artificial intelligence to manage this process.

Part of the reason that CareComm is working so well is because our team work elevates technology,” said Kelly Cullen, executive vice president and chief operating officer. “We’ve got teams from across the hospital – from nurses to transport staff to environmental services – sharing and acting upon information in CareComm to help our team members make sure our patients get the best care.” The center uses technology developed by GE Healthcare.

“Tampa General’s focus on team, patients and innovation was apparent from our first interaction,” said Jeff Terry, CEO of Clinical Command Centers for GE Healthcare. “It’s a terrific environment. The CareComm program includes a digital twin of TGH and a range of process improvement projects. Today is a terrific milestone for John and his team, the results are already impressive, and there’s so much innovation still ahead.”

CareComm’s features include:

  • 20 artificial intelligence apps, or “tiles,” from GE Healthcare. These tiles process hundreds of messages every minute, apply advanced analytics, and then provide decision support for CareComm staff
  • Individual “tiles” that monitor patient flow, track any delays in care, and even spot early warning signs that a patient’s health may be declining
  • 38 large screen LCDs so the tiles can be displayed with live data all the time
  • 4 of the LCDs are touch screens so staff can manipulate tiles during huddles and meetings
  • Carefully designed processes used by CareComm staff to help team members in the moment

Why are these changes important? It’s all about improving the care to patients – and improving their health outcomes.

Getting patients connected with nurses, doctors and hospital rooms at the soonest possible time often improves their care. “We all know the earlier you treat someone, the better the outcome is, generally speaking,” Chang said.

TGH hospital began a temporary scaled-down version of CareComm in December and moved into a new 8,000 square-foot headquarters on the hospital’s main campus today.

The coordination provided by CareComm also has enabled TGH to open a new Departure Lounge to further improve patients’ experience and patient flow. Instead of waiting in their hospital room to receive their take-home medicine or for their ride home, patients are now able to go to the lounge. It has comfortable chairs, televisions, wi-fi, plus free coffee and snacks. This allows patients to wait in a friendly and comfortable atmosphere, and it also opens up hospital beds sooner for those with acute needs.

“CareComm is the kind of innovation that Tampa General stands for,” Couris said. “Our commitment is to design a system that creates a sustainable and reproducible way to drive up the quality of care and lower of cost. We want to pass this value on to the patients, the payors, and the employers, creating a less expensive delivery model for health care in our state.”

 

SOURCE Tampa General Hospital

Related Topics:
Continue Reading

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

3 weeks ago

on

April 5, 2024

By

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

3 weeks ago

on

April 5, 2024

By

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

3 weeks ago

on

April 5, 2024

By

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending